Martin Hao, managing director at Healthera , questions the damage the new repeat prescribing model is having on community pharmacies

A controversial Clinical Commissioning Group (CCG) scheme that is banning some pharmacies from managing their patients’ repeat prescriptions has divided opinion in the sector.

While there are clear benefits of the scheme, and parts of it have managed to save the NHS money, it is clear to see that the negative impact on pharmacies has not been properly considered and the – more significant – underlying factors behind the issue itself have been overshadowed by statements of blame.

The picture painted by CCGs that are backing the repeat prescription scheme is simply that UK pharmacies are purposely or inefficiently over-ordering patient prescriptions in order to boost their dispensing income.

While this may be true for a select few pharmacies, it seems wrong to tarnish every chemist in the UK with the same brush. In fact, to state so resolutely that pharmacies are commonly wasting resources paints all community pharmacies in the same negative light despite the fact there simply isn’t evidence that this is commonplace.

Think about the process before repeat prescription schemes. Patients would go to their local pharmacy to order their medicines and these orders would then make their way to GP practices in large batches – a process which relieved pressures on both GPs, pharmacies and patients alike.

Effectively, the new repeat prescription scheme has now increased the workload for GPs and has been proven to make simply ordering a repeat prescription confusing and difficult for patients, especially those who have busy lifestyles or are of an older demographic and suffering from issues such as dementia.

The pharmacy, medical practice and patient struggle caused by the new scheme in already affected areas is obvious, and the impact has no doubt been accentuated by a lack of consultation with pharmacies from their respective CCGs.

A scheme of this magnitude surely demands input and feedback from all parties involved. And this oversight has resulted in sour feelings and a significant step back in terms of collaboration progress between the organisations which help ensure patient safety and service delivery in a cost-effective manner.

The bottom line is that this new scheme cuts pharmacies out of the loop, it negatively affects their business and also causes numerous problems for patients and for their GP practices.

Categories: Featured Article

Related Posts

Featured Article

Are you making the most of your pharmacy data?

Martin Hao, managing director of Healthera and Lewis Fiford, pharmacy innovation manager, explore how pharmacies can begin to use this data to their advantage to boost their business further. Pharmacies collect huge amounts of patient data, which Read more…

Featured Article

Pharmacies using technology to boost medical adherence

Medical adherence remains a challenge for all pharmacies but the technology is out there, as Martin Hao from Healthera explains… As consumers we are becoming ever-more curious about our health and fitness – many people Read more…

Featured Article

Can independents compete with the multiples?

– The Pharmacist Do multiples have the edge over independent pharmacies, ask Martin Hao, managing director at Healthera, and Lewis Fiford, pharmacy innovation manager It is clear that in the current UK pharmacy climate, the Read more…